ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. President and CEO Donn Casale will outline updated strategic priorities and report second quarter 2026 financial results. Dial-in details require event registration, while webcast access and slides will be available via the company’s website, with a replay accessible for 30 days.

Argus Aug 3 session 13 alerts

+6.43% close to close 0.5x rel. volume Open Argus

Details

Market reaction after 2Q26 earnings report: SPRY +6.43% in the Aug 3 session

+3.1% Peak Tracked

-9.5% Trough Tracked

$536.80M Market Cap

In the Aug 3 session, SPRY gained 6.43%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.4% in the session following this news. -0.94% was the average 24-hour move across...

Analysis

The stock moved +6.4% in the session following this news. -0.94% was the average 24-hour move across five comparable conference-and-earnings announcements. A strong positive response would contrast with that record; high short positioning remained a sourced volatility risk, while upcoming results provided the factual catalyst.

Key Figures

Reporting period: Q2 2026 Conference date: August 13, 2026 Call time: 1:30 p.m. PT / 4:30 p.m. ET +3 more

Reporting period

Q2 2026

Financial results to be reported during the call

Conference date

August 13, 2026

Conference call and webcast

Call time

1:30 p.m. PT / 4:30 p.m. ET

Scheduled conference call and webcast

Replay availability

30 days

Webcast replay following the event

U.S. pediatric weight threshold

33 lbs

neffy U.S. indication

EU pediatric weight threshold

30 kg

neffy EU indication

Previous Conferences,earnings Reports

5 past events · Latest: May 07

Same Type 5 events

1. May 07

   Q1 earnings call

   24h Move

   -3.0%

   Scheduled discussion of first-quarter results and business highlights

2. Feb 23

   Q4 earnings call

   24h Move

   +2.3%

   Scheduled fourth-quarter and full-year results discussion

3. Nov 03

   Q3 earnings call

   24h Move

   -3.8%

   Scheduled third-quarter results and business highlights discussion

4. Aug 04

   Q2 earnings call

   24h Move

   +1.2%

   Scheduled discussion of second-quarter results and business highlights

5. May 05

   Q1 earnings call

   24h Move

   -1.4%

   Scheduled first-quarter results and business highlights discussion

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

anaphylaxis, epinephrine, idiopathic

3 terms

anaphylaxis medical

"allergic reactions that could lead to anaphylaxis"

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

epinephrine medical

"an epinephrine nasal spray indicated in the U.S."

Epinephrine, also known as adrenaline, is a fast-acting hormone and medication used to stimulate the heart, open airways and tighten blood vessels during life-threatening emergencies like severe allergic reactions, asthma attacks and cardiac arrest. Investors care because its clinical use and demand drive sales of drug products and delivery devices, influence regulatory approvals and supply chains, and can quickly affect revenue and stock value when shortages, new formulations or policy changes occur.

idiopathic medical

"idiopathic or exercise induced anaphylaxis"

Idiopathic describes a medical condition or event for which no cause can be identified after reasonable investigation. For investors, seeing this term in clinical reports or safety updates signals uncertainty about why something happened, which can affect how regulators, insurers, or trial sponsors assess risk and future costs—like seeing a mysterious leak in a building with no obvious source.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.

Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® (trade name EURneffy^® in the EU and 优敏速^® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com

ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the ARS Pharmaceuticals (SPRY) Q2 2026 earnings conference call?

The ARS Pharmaceuticals Q2 2026 earnings conference call is scheduled for Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. According to ARS Pharmaceuticals, the event will cover updated strategic priorities and second quarter 2026 financial results.

How can investors access the ARS Pharmaceuticals (SPRY) Q2 2026 webcast on August 13, 2026?

Investors can access the ARS Pharmaceuticals Q2 2026 webcast via the Events & Presentations page in the Investors & Media section of the company website. According to ARS Pharmaceuticals, slides will be available there alongside the live webcast stream.

How do I obtain dial-in information for the ARS Pharmaceuticals (SPRY) August 13, 2026 earnings call?

Dial-in information for the ARS Pharmaceuticals August 13, 2026 earnings call is available by registering for the event. According to ARS Pharmaceuticals, registered participants will receive the necessary conference call access details before the scheduled start time.

Will a replay be available for the ARS Pharmaceuticals (SPRY) Q2 2026 earnings webcast?

Yes, a replay of the ARS Pharmaceuticals Q2 2026 earnings webcast will be available for 30 days following the event. According to ARS Pharmaceuticals, the replay can be accessed through the same Events & Presentations page on the company website.

What will ARS Pharmaceuticals (SPRY) discuss on the August 13, 2026 conference call?

On August 13, 2026, ARS Pharmaceuticals will outline its updated strategic priorities and report second quarter 2026 financial results. According to ARS Pharmaceuticals, President and CEO Donn Casale will lead the presentation during the conference call and webcast.

What does ARS Pharmaceuticals (SPRY) do and what is neffy?

ARS Pharmaceuticals is a biopharmaceutical company focused on protecting at-risk patients from allergic reactions that could lead to anaphylaxis. According to ARS Pharmaceuticals, it is commercializing neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis.